# Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2

> **NCT06790303** · PHASE2 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 8 (actual)

## Conditions studied

- Neoplasms

## Interventions

- **DRUG:** Feladilimab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT06790303
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-03-04
- **Primary completion:** 2021-09-23
- **Final completion:** 2021-09-23
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Due to low enrolment of participants
- **Last updated:** 2025-06-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06790303

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06790303, "Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC) - Sub-study 2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT06790303. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*